| A432 |
IMC-2C5 Biosimilar（Anti-PDGFRB / CD140b Reference Antibody）
Featured
|
|
|
| A433 |
Novo Nordisk patent anti-PGLYRP1 Biosimilar（Anti-PGLYRP1 / PGRP-S Reference Antibody）
Featured
|
|
|
| A434 |
Bavituximab Biosimilar（Anti-Phosphatidylserine Reference Antibody）
Featured
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. |
|
| A435 |
ATH3G10 Biosimilar（Anti-Phosphorylcholine Reference Antibody）
Featured
|
|
|
| A436 |
Diaccurate patent anti-sPLA2-GIB Biosimilar(Anti-PLA2G1B Reference Antibody)
Featured
|
|
|
| A437 |
ATN-658 Biosimilar（Anti-PLAUR / uPAR / CD87 Reference Antibody）
Featured
|
|
|
| A438 |
Genentech anti-PMEL17 Biosimilar（Anti-PMEL Reference Antibody）
Featured
|
|
|
| A439 |
Novartis patent anti-PMEL17 Biosimilar(Anti-PMEL Reference Antibody)
Featured
|
|
|
| A440 |
Genentech patent anti-Polyubiquitin Biosimilar(Anti-Polyubiquitin Reference Antibody)
Featured
|
|
|
| A441 |
Eureka patent anti-PRAME Biosimilar(Anti-PRAME Reference Antibody)
Featured
|
|
|
| A442 |
BAY-1158061
Featured
|
|
|
| A443 |
Rolinsatamab
Featured
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (C242, C242'). |
|
| A444 |
Forerunner patent anti-Prominin-1
Featured
|
|
|
| A445 |
AGS-1C4D4
Featured
|
|
|
| A446 |
Inclacumab
Featured
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion. |
|
| A447 |
Neihulizumab
Featured
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research. |
|
| A448 |
AG02-ADC
Featured
|
|
|
| DC65219 |
ACT-777991
Featured
|
ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.
|
|
| DC67080 |
Tri-GalNAc(OAc)3-Perfluorophenyl
Featured
|
Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: lysosome-targeting chimera. |
|
| DC60672 |
BAY-184
Featured
|
BAY-184 is the first, potent and selective acylsulfonamide-benzofuran in vivo-active KAT6A/B inhibitor with IC50 of 71 nM. |
|
| DC67081 |
CY5-SE
Featured
|
Cy5-SE (Cy5 NHS Ester) is a reactive dye for the labeling of amino-groups in peptides, proteins, and oligonucleotides. This dye requires small amount of organic co-solvent (such as DMF or DMSO) to be used in labeling reaction. This reagent is ideal for very cost-efficient labeling of soluble proteins, as well as all kinds of peptides and oligonucleotides. This reagent also works well in organic solvents for small molecule labeling. Excitation (nm):649, Emission (nm): 670. |
|
| DC60674 |
XY-07-191
Featured
|
XY-07-191 is the negative control of XY-07-35. |
|
| DC60675 |
MrTAC-HaXS8
Featured
|
MrTAC-HaXS8 is a methylarginine targeting chimera (MrTAC). MrTAC-HaXS8 induces lysosomal GSK3β proteolysis with DC50 of 11.3 nM. |
|
| DC60676 |
MRT-6160
Featured
|
MRT-6160 is a first-in-class molecular glue degrader that specifically targets VAV1 for proteasomal degradation with DC50 of 7 nM. |
|
| DC60677 |
Compound 31 (MerTK inhibitor)
Featured
|
Compound 31 (MerTK inhibitor) is a potent azetidine-benzoxazole MerTK inhibitor with IC50 of 1.3 nM. Compound 31 potently engages the target in vivo and demonstrates single agent activity in the immune-driven MC-38 murine syngeneic tumor model. |
.jpg)
|
| DC60678 |
ALG-055009
Featured
|
ALG-055009 is a potent and selective thyroid hormone receptor beta (THR-β) agonist with EC50 of 0.063 μM. ALG-055009 is highly metabolically stable, with good permeability and a relatively low efflux ratio. |
|
| DC60679 |
DYR684
Featured
|
DYR684 is a potent, selective, and metabolically stable PROTAC of the protein kinases DYRK1A and DYRK1B with Kd of 6.3 nM and 16 nM, respectively. |
|
| DC67083 |
INDEX NAME NOT YET ASSIGNED
Featured
|
|
|
| DC60680 |
AMG 193
Featured
|
AMG 193 is an orally bioavailable and MTA-cooperative PRMT5 inhibitor with IC50 of 0.107 μM in MTAP-null cells, which is about 40-fold selective over MTAP WT cells. |
|
| DC60681 |
SD-436
Featured
|
SD-436 is a highly potent and selective STAT3 degrader with DC50 of 0.1 nM in human PBMCs and displays >10,000-fold degradation selectivity for STAT3 over other STAT proteins. |
|
